

22 March 2017

## Omni Innovation Completes UK Licence Agreement - Distribution to Begin July 2017

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

### UK Distribution

Following the execution of a term sheet in November 2016, Omni Innovation has completed a licencing agreement with Healthspan in the UK. Healthspan is the UK's number one direct supplier of vitamins and supplements. The agreement is a 15-year exclusive licence to manufacture and distribute Omni Innovation's novel pre-meal drink for diabetes management in the UK subject to meeting increasing sales milestones. In addition to the on-going royalty, Omni Innovation will receive an upfront licencing fee.

Both parties are working on the development of a marketing plan to support the product launch, with product branding and manufacture to be undertaken by Healthspan. The product is expected to be available for sale in the UK by no later than 31 July 2017.

According to Diabetes UK<sup>i</sup>, since 1996, the number of people living with diabetes in the UK has more than doubled from 1.4 million to almost 3.5 million. Factoring in those with undiagnosed diabetes the figure rises to 4 million people and is expected to grow to 5 million by 2025. Of those living with diabetes in the UK 90% have type 2 diabetes. Additionally, Diabetes related health expenditure in the UK was estimated to be USD\$13b in 2015 as per the International Diabetes Foundation<sup>ii</sup>.

### About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit [www.eveinvestments.com.au](http://www.eveinvestments.com.au) and follow us on Twitter @EVEInvestments

### About Omni Innovation

Omni Innovation is a private Melbourne based medical nutrition company. Omni Innovation have, and continue to develop clinically validated and evidence-based dietary interventions in the areas of type-2 diabetes, pre-diabetes, medical weight management to improve health and quality of life.

In 2016 a license to Symbion Ltd (EBOS Ltd) was granted for the distribution of Faulding® GlucoControl™ for the dietary management of type 2 diabetes and pre-diabetes for release to the Australian market under their fully owned Faulding® brand.

For more information, please visit [www.omniinnovation.com.au](http://www.omniinnovation.com.au)

<sup>i</sup> <http://www.diabetes.co.uk/diabetes-prevalence.html>

<sup>ii</sup> <http://www.diabetesatlas.org/>